AC Immune Ltd Earnings

The next earnings date for AC Immune Ltd is August 3, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of AC Immune Ltd Earnings

Report Date	Estimated Earnings Per Share
08/03/2026	$-0.07

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

AC Immune Ltd Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
04/30/2026	Before Market	$-0.15	3.29%
03/13/2026	Before Market	$-0.13	24.29%
11/04/2025	Before Market	$-0.16	17.95%
08/05/2025	Before Market	$-0.21	-17.98%
04/30/2025	Before Market	$-0.19	9.13%
03/13/2025	Before Market	$-0.16	16.27%
11/05/2024	Before Market	$0.05	125.04%
08/06/2024	Before Market	$-0.23	-183.76%
05/13/2024	Before Market	$-0.18	-30.62%
03/14/2024	Before Market	$-0.05	56.75%
11/03/2023	Before Market	$-0.18	-787.02%
08/04/2023	Before Market	$-0.20	0.65%
04/28/2023	Before Market	$-0.21	10.29%
03/16/2023	Before Market	$-0.23	10.54%
10/28/2022	Before Market	$-0.16	35.12%
07/28/2022	Before Market	$-0.23	2.95%
04/28/2022	After Market	$-0.23	-1.77%
03/22/2022	Before Market	$-0.28	-367.75%
11/08/2021	Before Market	$-0.22	20.69%
08/04/2021	Before Market	$-0.26	-6.08%
04/28/2021	Before Market	$-0.23	2.17%
03/23/2021	Before Market	$-0.27	-7.06%
11/13/2020	Before Market	$-0.24	4.72%
08/05/2020	Before Market	$-0.22	12.59%
05/04/2020	Before Market	$-0.11	24.76%
03/30/2020	Before Market	$-0.28	-24.78%
11/13/2019	Before Market	$0.25	44.18%
08/14/2019	Before Market	$-0.24	-6.95%
05/15/2019	Before Market	$0.96	-22.00%
03/21/2019	Before Market	$-0.20	-156.42%
11/13/2018	Before Market	$-0.21	17.65%
08/08/2018	Before Market	$-0.19	17.21%
05/02/2018	After Market	$-0.20	6.93%
03/20/2018	Before Market	$0.08	769.57%
11/13/2017	Before Market	$-0.15	-17.37%
08/09/2017	Before Market	$-0.14	13.69%
05/11/2017	Before Market	$-0.17	-1.01%
11/11/2016	Before Market	$-0.18	-10.29%

More About AC Immune Ltd

Website

https://www.acimmune.com

Country

USA

Full Time Employees

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

“AC Immune Ltd Earnings” Can Refer to the AC Immune Ltd Earnings Date

Some people say “AC Immune Ltd earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my AC Immune Ltd position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning AC Immune Ltd Stock on the Earnings Date

If you own AC Immune Ltd stock (ACIU) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for AC Immune Ltd might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading AC Immune Ltd shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More AC Immune Ltd Earnings

You can contact us any time if you would like to ask questions about AC Immune Ltd earnings or anything else related to the stock market.